化酶5抑制剂的进展:揭示当前和未来的前景
Ahmed K ElHady1, Dalia S El-Gamil2, Mohammad Abdel-Halim3
1School of Life and Medical Sciences, University of Hertfordshire Hosted by Global Academic Foundation, New Administrative Capital, Cairo 11865, Egypt.
Pharmaceuticals (Basel, Switzerland)
|September 28, 2023
概括
基化酶5 (PDE5) 抑制剂显示出除了勃起功能障碍和肺动脉高血压之外的前景. 新的研究探索了它们在治疗各种疾病方面的潜力,重点是提高选择性和新型全抑制剂.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
背景情况:
- 基化酶5 (PDE5) 抑制剂是氧化/cGMP通路的关键调节剂.
- 它们的治疗应用范围超出了勃起功能障碍 (ED) 和肺动脉高血压 (PAH).
研究的目的:
- 为提供PDE5抑制剂作为疾病修饰剂的最新评估.
- 讨论PDE5抑制剂药物发现的最新进展,重点关注选择性和新机制.
主要方法:
- 在过去10年中发表的PDE5抑制剂的全面审查.
- 结合特征和异酶选择性的分析.
- 探索全抑制剂和多向配体的研究.
主要成果:
- PDE5 抑制剂在治疗包括认知功能障碍,心力衰竭和癌症在内的各种疾病方面具有潜力.
- 对于传统的PDE5抑制剂来说,有限的异酶选择性仍然是一个挑战.
- 新型全osteric PDE5 抑制剂提供了增强的选择性和治疗潜力.
结论:
- PDE5 抑制剂是具有扩展应用的多功能治疗剂.
- 药物化学的进步正在产生更有选择性和更强大的抑制剂.
- 菌抑制剂代表了一项重大突破,提供了改进的治疗特征.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
177
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
177
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
203
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
203
Dipeptidyl Peptidase 4 Inhibitors
204
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
204
Pharmacodynamics: Overview and Principles
1.2K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
1.2K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Drug Administration and Therapy Phases: Overview
504
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
504


